bmiMD vs Hers: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher

48 providers verified independently·Independent research·How we rank →

bmiMD beats Hers overall, scoring 8/10 vs 7.3/10. Hers is more affordable at $199/mo vs $319/mo. Choose bmiMD for budget-first users who want affordable glp-1 access. Choose Hers for women who want brand-name wegovy (injection or pill) at $149.

A side-by-side comparison of bmiMD and Hers covering pricing, scores, medication types, insurance, and more to help you decide.

Higher Rated

bmiMD

#9 of 48

8/10

Budget-friendly GLP-1 platform offering both medication types at one of the lowest price points in the market.

Visit bmiMD

Hers

#35 of 48

7.3/10

The women's health arm of Hims & Hers Health (NYSE: HIMS). In 2026 Hers signed a direct Novo Nordisk partnership adding FDA-approved Wegovy (pen and pill) at $149/mo and Zepbound via the Lilly partnership — alongside their existing compounded semaglutide and new compounded tirzepatide programs.

Visit Hers

Feature	bmiMD	Hers
Our Score	8/10	7.3/10
Starting Price	$319/mo	$199/mo
Medication Type	Both	Both
Insurance Accepted	No	No
Best For	Budget-first users who want affordable GLP-1 access	Women who want brand-name Wegovy (injection or pill) at $149/mo via the 2026 Novo Nordisk partnership, or a compounded semaglutide option from a publicly traded telehealth brand
Ranking	#9	#35

Pros & Cons Compared

bmiMD

Pros

+Same-day physician consults — one of the few platforms offering telehealth appointments the same day you apply
+80,000+ customer base with 4.9-star Trustpilot rating provides strong social proof of reliability
+100% money-back guarantee if your consultation determines you don't qualify for GLP-1 treatment
+HSA/FSA accepted for all programs

Cons

−Starting at $289/mo for semaglutide — significantly more expensive than competitors at $99-199/mo
−$29.99 shipping fee per order — most competitors include free shipping
−$50 non-refundable cancellation fee after intake approval — penalizes patients who change their mind

Hers

Pros

+2026 Novo Nordisk partnership — FDA-approved Wegovy pen and Wegovy oral pill from $149/mo, one of the lowest brand-name GLP-1 prices on the market
+Zepbound access via the Lilly/Hims-Hers partnership announced 2026
+Publicly traded company (NYSE: HIMS) with strong financial backing and regulatory compliance
+Broader women's health platform — integrates weight loss with hormonal, skin, and wellness services

Cons

−Membership + medication are billed separately ($39 first month / $149 ongoing membership) — watch the all-in math
−Generic support experience — large patient volume means less personalized attention
−Compounded pricing starts at $199/mo but stepped pricing applies at higher doses
−Zepbound access priced at ~$1,899/mo (brand cash) via the Lilly partnership — read as access, not value

Our Verdict

bmiMD edges out Hers with a score of 8/10 vs 7.3/10. If budget is your priority, Hers starts at $199/mo compared to bmiMD's $319/mo. Choose bmiMD if you want: budget-first users who want affordable glp-1 access. Choose Hers if you want: women who want brand-name wegovy (injection or pill) at $149/mo via the 2026 novo nordisk partnership, or a compounded semaglutide option from a publicly traded telehealth brand.

Still undecided? Editor's #1 Overall Pick

Embody

$299/mo · 7.3/10 · Compounded

If neither bmiMD nor Hers feels like the right fit, our overall #1 pick across all 48 GLP-1 telehealth providers is Embody — strongest balance of clinical oversight, transparent pricing, and verified availability.

Visit Embody→Read our full Embody review